BG64357B1 - С-4"-заместени макролидни производни - Google Patents

С-4"-заместени макролидни производни Download PDF

Info

Publication number: BG64357B1
Authority: BG; Bulgaria
Prior art keywords: compound; groups; hydroxy; formula; alkyl
Prior art date: 1997-06-11

Application number

BG103969A

Other languages

Bulgarian (bg)

English (en)

Other versions

BG103969A (en

Inventor

Brian Bronk

Takushi Kaneko

Michael LETAVIC

Hengmiao Cheng

Edward Glazer

Bingwei YANG

Original Assignee

Pfizer Products Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-06-11

Filing date

1999-12-08

Publication date

2004-11-30

1999-12-08 Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.

2000-07-31 Publication of BG103969A publication Critical patent/BG103969A/xx

2004-11-30 Publication of BG64357B1 publication Critical patent/BG64357B1/bg

Links

239000003120 macrolide antibiotic agent Substances 0.000 title description 19
150000001875 compounds Chemical class 0.000 claims abstract description 272
238000000034 method Methods 0.000 claims abstract description 57
150000003839 salts Chemical class 0.000 claims abstract description 39
238000002360 preparation method Methods 0.000 claims abstract description 19
208000022362 bacterial infectious disease Diseases 0.000 claims abstract description 17
208000035143 Bacterial infection Diseases 0.000 claims abstract description 16
238000011282 treatment Methods 0.000 claims abstract description 12
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 5
-1 3-methoxypropyl Chemical group 0.000 claims description 79
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 78
229920006395 saturated elastomer Polymers 0.000 claims description 50
229910052799 carbon Inorganic materials 0.000 claims description 36
229910052739 hydrogen Inorganic materials 0.000 claims description 30
125000000217 alkyl group Chemical group 0.000 claims description 28
125000003118 aryl group Chemical group 0.000 claims description 28
125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 27
125000006374 C2-C10 alkenyl group Chemical group 0.000 claims description 20
125000005843 halogen group Chemical group 0.000 claims description 20
125000005865 C2-C10alkynyl group Chemical group 0.000 claims description 19
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 19
125000001072 heteroaryl group Chemical group 0.000 claims description 18
125000001424 substituent group Chemical group 0.000 claims description 16
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 14
WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 claims description 14
229910052717 sulfur Inorganic materials 0.000 claims description 14
241000124008 Mammalia Species 0.000 claims description 13
125000004093 cyano group Chemical group *C#N 0.000 claims description 13
241000251468 Actinopterygii Species 0.000 claims description 12
206010037075 Protozoal infections Diseases 0.000 claims description 12
241000271566 Aves Species 0.000 claims description 10
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 9
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 claims description 9
GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 claims description 8
125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 8
239000003814 drug Substances 0.000 claims description 8
229910052757 nitrogen Inorganic materials 0.000 claims description 8
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 7
125000005842 heteroatom Chemical group 0.000 claims description 7
125000002971 oxazolyl group Chemical group 0.000 claims description 7
229910052760 oxygen Inorganic materials 0.000 claims description 7
239000012312 sodium hydride Substances 0.000 claims description 7
229910000104 sodium hydride Inorganic materials 0.000 claims description 7
125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 claims description 6
125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims description 6
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 6
CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 claims description 6
239000011203 carbon fibre reinforced carbon Substances 0.000 claims description 6
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 6
125000002950 monocyclic group Chemical group 0.000 claims description 6
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
125000003367 polycyclic group Chemical group 0.000 claims description 6
MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 claims description 6
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 6
KYVBNYUBXIEUFW-UHFFFAOYSA-N 1,1,3,3-tetramethylguanidine Chemical compound CN(C)C(=N)N(C)C KYVBNYUBXIEUFW-UHFFFAOYSA-N 0.000 claims description 4
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 4
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 4
LINDOXZENKYESA-UHFFFAOYSA-N TMG Natural products CNC(N)=NC LINDOXZENKYESA-UHFFFAOYSA-N 0.000 claims description 4
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 4
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims description 4
230000008569 process Effects 0.000 claims description 4
QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 claims description 4
SGUVLZREKBPKCE-UHFFFAOYSA-N 1,5-diazabicyclo[4.3.0]-non-5-ene Chemical compound C1CCN=C2CCCN21 SGUVLZREKBPKCE-UHFFFAOYSA-N 0.000 claims description 3
125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 3
125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 3
125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 3
125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 3
HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 3
HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims description 3
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 3
125000002883 imidazolyl group Chemical group 0.000 claims description 3
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 3
RPDAUEIUDPHABB-UHFFFAOYSA-N potassium ethoxide Chemical compound [K+].CC[O-] RPDAUEIUDPHABB-UHFFFAOYSA-N 0.000 claims description 3
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 3
229920002554 vinyl polymer Polymers 0.000 claims description 3
125000006019 1-methyl-1-propenyl group Chemical group 0.000 claims description 2
125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims description 2
125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims description 2
125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 claims description 2
QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 claims description 2
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 2
125000003545 alkoxy group Chemical group 0.000 claims description 2
FATAVLOOLIRUNA-UHFFFAOYSA-N formylmethyl Chemical group [CH2]C=O FATAVLOOLIRUNA-UHFFFAOYSA-N 0.000 claims description 2
125000002346 iodo group Chemical group I* 0.000 claims description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 claims description 2
LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical group [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 claims description 2
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
125000001425 triazolyl group Chemical group 0.000 claims description 2
230000000844 anti-bacterial effect Effects 0.000 abstract description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 113
239000000243 solution Substances 0.000 description 98
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 63
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 44
239000000460 chlorine Substances 0.000 description 43
239000011541 reaction mixture Substances 0.000 description 34
239000012267 brine Substances 0.000 description 30
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 30
208000015181 infectious disease Diseases 0.000 description 29
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 26
235000019439 ethyl acetate Nutrition 0.000 description 26
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 26
239000011734 sodium Chemical group 0.000 description 25
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 24
239000000203 mixture Substances 0.000 description 23
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 22
239000007787 solid Substances 0.000 description 20
239000002904 solvent Substances 0.000 description 19
238000006243 chemical reaction Methods 0.000 description 17
238000010898 silica gel chromatography Methods 0.000 description 17
LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 16
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 16
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 15
230000001580 bacterial effect Effects 0.000 description 15
239000000284 extract Substances 0.000 description 14
239000000047 product Substances 0.000 description 14
238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 13
239000010410 layer Substances 0.000 description 13
125000002927 2-methoxybenzyl group Chemical group [H]C1=C([H])C([H])=C(C(OC([H])([H])[H])=C1[H])C([H])([H])* 0.000 description 12
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
239000002585 base Substances 0.000 description 12
235000017557 sodium bicarbonate Nutrition 0.000 description 12
229910000030 sodium bicarbonate Inorganic materials 0.000 description 12
238000003756 stirring Methods 0.000 description 12
238000012360 testing method Methods 0.000 description 12
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 11
238000004458 analytical method Methods 0.000 description 11
239000012044 organic layer Substances 0.000 description 11
230000002829 reductive effect Effects 0.000 description 11
238000000926 separation method Methods 0.000 description 11
229910052727 yttrium Inorganic materials 0.000 description 11
229910004298 SiO 2 Inorganic materials 0.000 description 10
239000002253 acid Substances 0.000 description 10
239000008186 active pharmaceutical agent Substances 0.000 description 10
238000001704 evaporation Methods 0.000 description 10
AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 10
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 9
241001465754 Metazoa Species 0.000 description 9
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
239000012043 crude product Substances 0.000 description 9
230000008020 evaporation Effects 0.000 description 9
NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 9
241000283690 Bos taurus Species 0.000 description 8
239000003153 chemical reaction reagent Substances 0.000 description 8
229910052943 magnesium sulfate Inorganic materials 0.000 description 8
235000019341 magnesium sulphate Nutrition 0.000 description 8
239000003960 organic solvent Substances 0.000 description 8
239000000741 silica gel Substances 0.000 description 8
229910002027 silica gel Inorganic materials 0.000 description 8
239000007858 starting material Substances 0.000 description 8
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical class O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 7
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 7
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 7
241000606856 Pasteurella multocida Species 0.000 description 7
241000193996 Streptococcus pyogenes Species 0.000 description 7
229940079593 drug Drugs 0.000 description 7
238000001035 drying Methods 0.000 description 7
230000000694 effects Effects 0.000 description 7
229910052708 sodium Inorganic materials 0.000 description 7
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 6
241000193998 Streptococcus pneumoniae Species 0.000 description 6
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
150000007513 acids Chemical class 0.000 description 6
125000003277 amino group Chemical group 0.000 description 6
PKSROMPNLONTJT-UHFFFAOYSA-N azanium;chloroform;methanol;hydroxide Chemical compound N.O.OC.ClC(Cl)Cl PKSROMPNLONTJT-UHFFFAOYSA-N 0.000 description 6
239000001257 hydrogen Substances 0.000 description 6
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
239000000543 intermediate Substances 0.000 description 6
238000004519 manufacturing process Methods 0.000 description 6
230000004048 modification Effects 0.000 description 6
238000012986 modification Methods 0.000 description 6
KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
229910052700 potassium Inorganic materials 0.000 description 6
239000011591 potassium Substances 0.000 description 6
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
238000000746 purification Methods 0.000 description 6
229940031000 streptococcus pneumoniae Drugs 0.000 description 6
241000588724 Escherichia coli Species 0.000 description 5
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
241001293418 Mannheimia haemolytica Species 0.000 description 5
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 5
241000191967 Staphylococcus aureus Species 0.000 description 5
150000001412 amines Chemical class 0.000 description 5
239000007864 aqueous solution Substances 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
239000007788 liquid Substances 0.000 description 5
125000006239 protecting group Chemical group 0.000 description 5
239000001632 sodium acetate Substances 0.000 description 5
235000017281 sodium acetate Nutrition 0.000 description 5
239000000725 suspension Substances 0.000 description 5
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
241000194017 Streptococcus Species 0.000 description 4
150000001414 amino alcohols Chemical class 0.000 description 4
239000003242 anti bacterial agent Substances 0.000 description 4
229940088710 antibiotic agent Drugs 0.000 description 4
229960004099 azithromycin Drugs 0.000 description 4
MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 4
230000003197 catalytic effect Effects 0.000 description 4
150000001768 cations Chemical class 0.000 description 4
MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 4
238000004587 chromatography analysis Methods 0.000 description 4
238000001816 cooling Methods 0.000 description 4
208000035475 disorder Diseases 0.000 description 4
238000005516 engineering process Methods 0.000 description 4
238000000605 extraction Methods 0.000 description 4
238000001914 filtration Methods 0.000 description 4
239000012467 final product Substances 0.000 description 4
239000011777 magnesium Substances 0.000 description 4
229910052749 magnesium Inorganic materials 0.000 description 4
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
150000007522 mineralic acids Chemical class 0.000 description 4
231100000252 nontoxic Toxicity 0.000 description 4
230000003000 nontoxic effect Effects 0.000 description 4
150000007524 organic acids Chemical class 0.000 description 4
MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 4
229910003446 platinum oxide Inorganic materials 0.000 description 4
238000003752 polymerase chain reaction Methods 0.000 description 4
PKZJLOCLABXVMC-UHFFFAOYSA-N 2-Methoxybenzaldehyde Chemical compound COC1=CC=CC=C1C=O PKZJLOCLABXVMC-UHFFFAOYSA-N 0.000 description 3
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
241000282472 Canis lupus familiaris Species 0.000 description 3
241000193403 Clostridium Species 0.000 description 3
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
241000282326 Felis catus Species 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
241000606768 Haemophilus influenzae Species 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
230000002378 acidificating effect Effects 0.000 description 3
150000001447 alkali salts Chemical class 0.000 description 3
229910052784 alkaline earth metal Inorganic materials 0.000 description 3
239000007621 bhi medium Substances 0.000 description 3
239000011575 calcium Substances 0.000 description 3
229910052791 calcium Inorganic materials 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
229920001577 copolymer Polymers 0.000 description 3
239000006071 cream Substances 0.000 description 3
229960001760 dimethyl sulfoxide Drugs 0.000 description 3
125000003700 epoxy group Chemical group 0.000 description 3
229960003276 erythromycin Drugs 0.000 description 3
239000000706 filtrate Substances 0.000 description 3
239000012458 free base Substances 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
229960004592 isopropanol Drugs 0.000 description 3
229940041033 macrolides Drugs 0.000 description 3
NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 3
238000004949 mass spectrometry Methods 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
229910052763 palladium Inorganic materials 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
239000000843 powder Substances 0.000 description 3
239000012321 sodium triacetoxyborohydride Substances 0.000 description 3
229940095064 tartrate Drugs 0.000 description 3
229940086542 triethylamine Drugs 0.000 description 3
GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
BEOBZEOPTQQELP-UHFFFAOYSA-N 4-(trifluoromethyl)benzaldehyde Chemical compound FC(F)(F)C1=CC=C(C=O)C=C1 BEOBZEOPTQQELP-UHFFFAOYSA-N 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
229920001817 Agar Polymers 0.000 description 2
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
241001148536 Bacteroides sp. Species 0.000 description 2
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
BMTAFVWTTFSTOG-UHFFFAOYSA-N Butylate Chemical group CCSC(=O)N(CC(C)C)CC(C)C BMTAFVWTTFSTOG-UHFFFAOYSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
241001647372 Chlamydia pneumoniae Species 0.000 description 2
241000606153 Chlamydia trachomatis Species 0.000 description 2
108010065152 Coagulase Proteins 0.000 description 2
206010010741 Conjunctivitis Diseases 0.000 description 2
XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
208000004232 Enteritis Diseases 0.000 description 2
241000194033 Enterococcus Species 0.000 description 2
108090000371 Esterases Proteins 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
MPCRDALPQLDDFX-UHFFFAOYSA-L Magnesium perchlorate Chemical compound [Mg+2].[O-]Cl(=O)(=O)=O.[O-]Cl(=O)(=O)=O MPCRDALPQLDDFX-UHFFFAOYSA-L 0.000 description 2
240000003183 Manihot esculenta Species 0.000 description 2
235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 2
241000588621 Moraxella Species 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 2
MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 2
206010062255 Soft tissue infection Diseases 0.000 description 2
241000295644 Staphylococcaceae Species 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
108010034396 Streptogramins Proteins 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
239000008272 agar Substances 0.000 description 2
239000000783 alginic acid Substances 0.000 description 2
235000010443 alginic acid Nutrition 0.000 description 2
229920000615 alginic acid Polymers 0.000 description 2
229960001126 alginic acid Drugs 0.000 description 2
150000004781 alginic acids Chemical class 0.000 description 2
229910052783 alkali metal Inorganic materials 0.000 description 2
150000001340 alkali metals Chemical class 0.000 description 2
230000000842 anti-protozoal effect Effects 0.000 description 2
239000012298 atmosphere Substances 0.000 description 2
125000004429 atom Chemical group 0.000 description 2
244000052616 bacterial pathogen Species 0.000 description 2
150000007514 bases Chemical class 0.000 description 2
HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
229910052794 bromium Inorganic materials 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
239000000969 carrier Substances 0.000 description 2
238000009903 catalytic hydrogenation reaction Methods 0.000 description 2
239000006285 cell suspension Substances 0.000 description 2
229940038705 chlamydia trachomatis Drugs 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
229960002626 clarithromycin Drugs 0.000 description 2
AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 2
238000005056 compaction Methods 0.000 description 2
239000010779 crude oil Substances 0.000 description 2
RAFNCPHFRHZCPS-UHFFFAOYSA-N di(imidazol-1-yl)methanethione Chemical compound C1=CN=CN1C(=S)N1C=CN=C1 RAFNCPHFRHZCPS-UHFFFAOYSA-N 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
235000019253 formic acid Nutrition 0.000 description 2
239000000499 gel Substances 0.000 description 2
229940047650 haemophilus influenzae Drugs 0.000 description 2
150000004820 halides Chemical class 0.000 description 2
229910052736 halogen Inorganic materials 0.000 description 2
150000002367 halogens Chemical class 0.000 description 2
125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
238000011081 inoculation Methods 0.000 description 2
229910052500 inorganic mineral Inorganic materials 0.000 description 2
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
239000002502 liposome Substances 0.000 description 2
MHCFAGZWMAWTNR-UHFFFAOYSA-M lithium perchlorate Chemical compound [Li+].[O-]Cl(=O)(=O)=O MHCFAGZWMAWTNR-UHFFFAOYSA-M 0.000 description 2
229910001486 lithium perchlorate Inorganic materials 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000002609 medium Substances 0.000 description 2
235000010755 mineral Nutrition 0.000 description 2
239000011707 mineral Substances 0.000 description 2
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
239000002674 ointment Substances 0.000 description 2
235000005985 organic acids Nutrition 0.000 description 2
229940014662 pantothenate Drugs 0.000 description 2
235000019161 pantothenic acid Nutrition 0.000 description 2
239000011713 pantothenic acid Substances 0.000 description 2
244000052769 pathogen Species 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
208000028172 protozoa infectious disease Diseases 0.000 description 2
230000035484 reaction time Effects 0.000 description 2
230000009257 reactivity Effects 0.000 description 2
230000008261 resistance mechanism Effects 0.000 description 2
208000023504 respiratory system disease Diseases 0.000 description 2
206010040872 skin infection Diseases 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000011550 stock solution Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000003826 tablet Substances 0.000 description 2
150000003573 thiols Chemical class 0.000 description 2
208000019206 urinary tract infection Diseases 0.000 description 2
238000005406 washing Methods 0.000 description 2
NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
OXHNLMTVIGZXSG-UHFFFAOYSA-N 1-Methylpyrrole Chemical compound CN1C=CC=C1 OXHNLMTVIGZXSG-UHFFFAOYSA-N 0.000 description 1
MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 description 1
PAKFHEFMTRCFAU-UHFFFAOYSA-N 2-bromo-1-(3,4-dichlorophenyl)ethanone Chemical compound ClC1=CC=C(C(=O)CBr)C=C1Cl PAKFHEFMTRCFAU-UHFFFAOYSA-N 0.000 description 1
FFNVQNRYTPFDDP-UHFFFAOYSA-N 2-cyanopyridine Chemical compound N#CC1=CC=CC=N1 FFNVQNRYTPFDDP-UHFFFAOYSA-N 0.000 description 1
ALKYHXVLJMQRLQ-UHFFFAOYSA-N 3-Hydroxy-2-naphthoate Chemical class C1=CC=C2C=C(O)C(C(=O)O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-N 0.000 description 1
YACFFSVYSPMSGS-UHFFFAOYSA-N 3-methoxyprop-1-yne Chemical compound COCC#C YACFFSVYSPMSGS-UHFFFAOYSA-N 0.000 description 1
QWLHJVDRPZNVBS-UHFFFAOYSA-N 4-phenoxybenzaldehyde Chemical compound C1=CC(C=O)=CC=C1OC1=CC=CC=C1 QWLHJVDRPZNVBS-UHFFFAOYSA-N 0.000 description 1
125000001318 4-trifluoromethylbenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])*)C(F)(F)F 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
241000606750 Actinobacillus Species 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
244000303258 Annona diversifolia Species 0.000 description 1
235000002198 Annona diversifolia Nutrition 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
241001518086 Bartonella henselae Species 0.000 description 1
241000588807 Bordetella Species 0.000 description 1
241000588832 Bordetella pertussis Species 0.000 description 1
241000589969 Borreliella burgdorferi Species 0.000 description 1
241001148534 Brachyspira Species 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
VAHDQANCNHZZQK-UHFFFAOYSA-N CCCO.CC(C)=O.CCCCCC Chemical compound CCCO.CC(C)=O.CCCCCC VAHDQANCNHZZQK-UHFFFAOYSA-N 0.000 description 1
101100037762 Caenorhabditis elegans rnh-2 gene Proteins 0.000 description 1
206010051226 Campylobacter infection Diseases 0.000 description 1
235000002566 Capsicum Nutrition 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
241000193468 Clostridium perfringens Species 0.000 description 1
241000224483 Coccidia Species 0.000 description 1
241000186216 Corynebacterium Species 0.000 description 1
241001518260 Corynebacterium minutissimum Species 0.000 description 1
206010011224 Cough Diseases 0.000 description 1
208000008953 Cryptosporidiosis Diseases 0.000 description 1
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
206010011844 Dacryocystitis Diseases 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
241000605721 Dichelobacter nodosus Species 0.000 description 1
ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
241000588914 Enterobacter Species 0.000 description 1
101100119095 Enterococcus faecalis (strain ATCC 700802 / V583) ermB gene Proteins 0.000 description 1
239000004593 Epoxy Substances 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
241000186394 Eubacterium Species 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
206010016952 Food poisoning Diseases 0.000 description 1
208000019331 Foodborne disease Diseases 0.000 description 1
241000605909 Fusobacterium Species 0.000 description 1
241000605952 Fusobacterium necrophorum Species 0.000 description 1
201000000628 Gas Gangrene Diseases 0.000 description 1
208000005577 Gastroenteritis Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
206010019375 Helicobacter infections Diseases 0.000 description 1
241000590002 Helicobacter pylori Species 0.000 description 1
239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
AMIMRNSIRUDHCM-UHFFFAOYSA-N Isopropylaldehyde Chemical compound CC(C)C=O AMIMRNSIRUDHCM-UHFFFAOYSA-N 0.000 description 1
241000588748 Klebsiella Species 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
241001148567 Lawsonia intracellularis Species 0.000 description 1
241000589242 Legionella pneumophila Species 0.000 description 1
239000002841 Lewis acid Substances 0.000 description 1
229910010082 LiAlH Inorganic materials 0.000 description 1
241000186781 Listeria Species 0.000 description 1
208000016604 Lyme disease Diseases 0.000 description 1
101150052154 MSRA1 gene Proteins 0.000 description 1
208000010315 Mastoiditis Diseases 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
241001024304 Mino Species 0.000 description 1
241000588622 Moraxella bovis Species 0.000 description 1
241000186367 Mycobacterium avium Species 0.000 description 1
241000186364 Mycobacterium intracellulare Species 0.000 description 1
241000204031 Mycoplasma Species 0.000 description 1
241001138504 Mycoplasma bovis Species 0.000 description 1
241000202934 Mycoplasma pneumoniae Species 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
241000588652 Neisseria gonorrhoeae Species 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
206010048685 Oral infection Diseases 0.000 description 1
206010031252 Osteomyelitis Diseases 0.000 description 1
208000005141 Otitis Diseases 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
241000191992 Peptostreptococcus Species 0.000 description 1
201000007100 Pharyngitis Diseases 0.000 description 1
241000758706 Piperaceae Species 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
229920000954 Polyglycolide Polymers 0.000 description 1
241000605861 Prevotella Species 0.000 description 1
102000055027 Protein Methyltransferases Human genes 0.000 description 1
108700040121 Protein Methyltransferases Proteins 0.000 description 1
206010057190 Respiratory tract infections Diseases 0.000 description 1
208000025747 Rheumatic disease Diseases 0.000 description 1
241000607142 Salmonella Species 0.000 description 1
206010040047 Sepsis Diseases 0.000 description 1
206010040070 Septic Shock Diseases 0.000 description 1
208000019802 Sexually transmitted disease Diseases 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
241000191940 Staphylococcus Species 0.000 description 1
241000191963 Staphylococcus epidermidis Species 0.000 description 1
241001147691 Staphylococcus saprophyticus Species 0.000 description 1
241000193985 Streptococcus agalactiae Species 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
241000282898 Sus scrofa Species 0.000 description 1
206010044248 Toxic shock syndrome Diseases 0.000 description 1
231100000650 Toxic shock syndrome Toxicity 0.000 description 1
241000589884 Treponema pallidum Species 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
241000202921 Ureaplasma urealyticum Species 0.000 description 1
208000006374 Uterine Cervicitis Diseases 0.000 description 1
206010046793 Uterine inflammation Diseases 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
241000606834 [Haemophilus] ducreyi Species 0.000 description 1
GHVZOJONCUEWAV-UHFFFAOYSA-N [K].CCO Chemical compound [K].CCO GHVZOJONCUEWAV-UHFFFAOYSA-N 0.000 description 1
206010000210 abortion Diseases 0.000 description 1
231100000176 abortion Toxicity 0.000 description 1
206010000269 abscess Diseases 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
229940022663 acetate Drugs 0.000 description 1
150000001242 acetic acid derivatives Chemical class 0.000 description 1
238000010306 acid treatment Methods 0.000 description 1
230000002411 adverse Effects 0.000 description 1
238000002814 agar dilution Methods 0.000 description 1
239000003513 alkali Substances 0.000 description 1
125000003342 alkenyl group Chemical group 0.000 description 1
125000000304 alkynyl group Chemical group 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
235000019270 ammonium chloride Nutrition 0.000 description 1
125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
230000000845 anti-microbial effect Effects 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
238000011203 antimicrobial therapy Methods 0.000 description 1
239000003904 antiprotozoal agent Substances 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
239000003849 aromatic solvent Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
229940092524 bartonella henselae Drugs 0.000 description 1
FXCLIEYDXXVEAI-UHFFFAOYSA-N benzene;dichloromethane Chemical compound ClCCl.C1=CC=CC=C1 FXCLIEYDXXVEAI-UHFFFAOYSA-N 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
229940077388 benzenesulfonate Drugs 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
OPBURCVWOKTFHZ-UHFFFAOYSA-N benzyl 1-hydroxy-2,5-dioxopyrrolidine-3-carboxylate Chemical compound O=C1N(O)C(=O)CC1C(=O)OCC1=CC=CC=C1 OPBURCVWOKTFHZ-UHFFFAOYSA-N 0.000 description 1
125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
229920002988 biodegradable polymer Polymers 0.000 description 1
239000004621 biodegradable polymer Substances 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
125000001246 bromo group Chemical group Br* 0.000 description 1
206010006451 bronchitis Diseases 0.000 description 1
230000005587 bubbling Effects 0.000 description 1
244000309464 bull Species 0.000 description 1
ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
229960003563 calcium carbonate Drugs 0.000 description 1
235000010216 calcium carbonate Nutrition 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
206010008323 cervicitis Diseases 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
229940001468 citrate Drugs 0.000 description 1
239000003086 colorant Substances 0.000 description 1
235000009508 confectionery Nutrition 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000006317 cyclopropyl amino group Chemical group 0.000 description 1
235000013365 dairy product Nutrition 0.000 description 1
238000001514 detection method Methods 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000003113 dilution method Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
208000019258 ear infection Diseases 0.000 description 1
101150092716 ectB gene Proteins 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
229940082150 encore Drugs 0.000 description 1
101150024162 eptB gene Proteins 0.000 description 1
101150016744 ermC gene Proteins 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
NISYDOWSZJJYCA-UHFFFAOYSA-N ethyl thiophene-2-carboximidate;hydrochloride Chemical compound Cl.CCOC(=N)C1=CC=CS1 NISYDOWSZJJYCA-UHFFFAOYSA-N 0.000 description 1
125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
239000012530 fluid Substances 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
125000001153 fluoro group Chemical group F* 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
238000001640 fractional crystallisation Methods 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
125000002541 furyl group Chemical group 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
229940050410 gluconate Drugs 0.000 description 1
229930195712 glutamate Natural products 0.000 description 1
229960002449 glycine Drugs 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
150000003278 haem Chemical class 0.000 description 1
229940037467 helicobacter pylori Drugs 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
239000000017 hydrogel Substances 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
238000005984 hydrogenation reaction Methods 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000036039 immunity Effects 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
239000011630 iodine Substances 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
TWBYWOBDOCUKOW-UHFFFAOYSA-M isonicotinate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 1
125000000842 isoxazolyl group Chemical group 0.000 description 1
235000015110 jellies Nutrition 0.000 description 1
206010023332 keratitis Diseases 0.000 description 1
229940001447 lactate Drugs 0.000 description 1
150000002596 lactones Chemical class 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229940115932 legionella pneumophila Drugs 0.000 description 1
150000007517 lewis acids Chemical class 0.000 description 1
229940041028 lincosamides Drugs 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
229910001496 lithium tetrafluoroborate Inorganic materials 0.000 description 1
244000144972 livestock Species 0.000 description 1
239000006210 lotion Substances 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
RMGJCSHZTFKPNO-UHFFFAOYSA-M magnesium;ethene;bromide Chemical compound [Mg+2].[Br-].[CH-]=C RMGJCSHZTFKPNO-UHFFFAOYSA-M 0.000 description 1
LROBJRRFCPYLIT-UHFFFAOYSA-M magnesium;ethyne;bromide Chemical compound [Mg+2].[Br-].[C-]#C LROBJRRFCPYLIT-UHFFFAOYSA-M 0.000 description 1
SCEZYJKGDJPHQO-UHFFFAOYSA-M magnesium;methanidylbenzene;chloride Chemical compound [Mg+2].[Cl-].[CH2-]C1=CC=CC=C1 SCEZYJKGDJPHQO-UHFFFAOYSA-M 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
238000001819 mass spectrum Methods 0.000 description 1
208000004396 mastitis Diseases 0.000 description 1
239000000463 material Substances 0.000 description 1
101150111763 mefA gene Proteins 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000011987 methylation Effects 0.000 description 1
238000007069 methylation reaction Methods 0.000 description 1
125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
238000002156 mixing Methods 0.000 description 1
101150021123 msrA gene Proteins 0.000 description 1
101150114366 msrA2 gene Proteins 0.000 description 1
101150006794 msrAB gene Proteins 0.000 description 1
101150109310 msrAB1 gene Proteins 0.000 description 1
101150052209 msrAB2 gene Proteins 0.000 description 1
229940013390 mycoplasma pneumoniae Drugs 0.000 description 1
SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
239000012299 nitrogen atmosphere Substances 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
239000008203 oral pharmaceutical composition Substances 0.000 description 1
239000007935 oral tablet Substances 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000006072 paste Substances 0.000 description 1
229940051027 pasteurella multocida Drugs 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
ANRQGKOBLBYXFM-UHFFFAOYSA-M phenylmagnesium bromide Chemical compound Br[Mg]C1=CC=CC=C1 ANRQGKOBLBYXFM-UHFFFAOYSA-M 0.000 description 1
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
125000005543 phthalimide group Chemical group 0.000 description 1
229960005235 piperonyl butoxide Drugs 0.000 description 1
239000002798 polar solvent Substances 0.000 description 1
229920000747 poly(lactic acid) Polymers 0.000 description 1
229920001610 polycaprolactone Polymers 0.000 description 1
229920002721 polycyanoacrylate Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000004633 polyglycolic acid Substances 0.000 description 1
239000004626 polylactic acid Substances 0.000 description 1
229920000656 polylysine Polymers 0.000 description 1
159000000001 potassium salts Chemical class 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
244000079416 protozoan pathogen Species 0.000 description 1
125000003373 pyrazinyl group Chemical group 0.000 description 1
125000003226 pyrazolyl group Chemical group 0.000 description 1
125000004076 pyridyl group Chemical group 0.000 description 1
125000000714 pyrimidinyl group Chemical group 0.000 description 1
125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
125000000168 pyrrolyl group Chemical group 0.000 description 1
150000003254 radicals Chemical class 0.000 description 1
238000005932 reductive alkylation reaction Methods 0.000 description 1
238000010992 reflux Methods 0.000 description 1
208000007865 relapsing fever Diseases 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
230000000552 rheumatic effect Effects 0.000 description 1
YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
229960001860 salicylate Drugs 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
201000009890 sinusitis Diseases 0.000 description 1
239000002002 slurry Substances 0.000 description 1
239000012279 sodium borohydride Substances 0.000 description 1
229910000033 sodium borohydride Inorganic materials 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
229960001790 sodium citrate Drugs 0.000 description 1
235000011083 sodium citrates Nutrition 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
238000009331 sowing Methods 0.000 description 1
241000894007 species Species 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
239000007921 spray Substances 0.000 description 1
229940041030 streptogramins Drugs 0.000 description 1
238000005556 structure-activity relationship Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
125000004354 sulfur functional group Chemical group 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000006188 syrup Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
235000012976 tarts Nutrition 0.000 description 1
MFPWEWYKQYMWRO-UHFFFAOYSA-N tert-butyl carboxy carbonate Chemical compound CC(C)(C)OC(=O)OC(O)=O MFPWEWYKQYMWRO-UHFFFAOYSA-N 0.000 description 1
DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 1
125000003831 tetrazolyl group Chemical group 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
125000000335 thiazolyl group Chemical group 0.000 description 1
125000001544 thienyl group Chemical group 0.000 description 1
CUPOOAWTRIURFT-UHFFFAOYSA-N thiophene-2-carbonitrile Chemical compound N#CC1=CC=CS1 CUPOOAWTRIURFT-UHFFFAOYSA-N 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
206010044008 tonsillitis Diseases 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
108091005703 transmembrane proteins Proteins 0.000 description 1
102000035160 transmembrane proteins Human genes 0.000 description 1
LEIMLDGFXIOXMT-UHFFFAOYSA-N trimethylsilyl cyanide Chemical compound C[Si](C)(C)C#N LEIMLDGFXIOXMT-UHFFFAOYSA-N 0.000 description 1
BPLKQGGAXWRFOE-UHFFFAOYSA-M trimethylsulfoxonium iodide Chemical compound [I-].C[S+](C)(C)=O BPLKQGGAXWRFOE-UHFFFAOYSA-M 0.000 description 1
231100000397 ulcer Toxicity 0.000 description 1
208000000143 urethritis Diseases 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Tropical Medicine & Parasitology (AREA)
Biotechnology (AREA)
Molecular Biology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

BG103969A 1997-06-11 1999-12-08 С-4"-заместени макролидни производни BG64357B1 (bg)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US4998097P	1997-06-11	1997-06-11

Publications (2)

Publication Number	Publication Date
BG103969A BG103969A (en)	2000-07-31
BG64357B1 true BG64357B1 (bg)	2004-11-30

Family

ID=21962765

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG103969A BG64357B1 (bg)	1997-06-11	1999-12-08	С-4"-заместени макролидни производни

Country Status (39)

Country	Link
EP (1)	EP0988309B1 (fr)
JP (1)	JP3262806B2 (fr)
KR (1)	KR100369959B1 (fr)
CN (1)	CN1145636C (fr)
AP (1)	AP1189A (fr)
AR (1)	AR013085A1 (fr)
AT (1)	ATE310742T1 (fr)
AU (1)	AU745006C (fr)
BG (1)	BG64357B1 (fr)
BR (1)	BR9810097A (fr)
CA (1)	CA2293397C (fr)
CO (1)	CO4950584A1 (fr)
DE (1)	DE69832486T2 (fr)
DZ (1)	DZ2515A1 (fr)
EA (1)	EA002440B1 (fr)
ES (1)	ES2251081T3 (fr)
GT (1)	GT199800075A (fr)
HN (1)	HN1998000074A (fr)
HR (1)	HRP980315A2 (fr)
HU (1)	HUP0004076A3 (fr)
ID (1)	ID24530A (fr)
IL (1)	IL132808A (fr)
IS (1)	IS1979B (fr)
MA (1)	MA24563A1 (fr)
MY (1)	MY133027A (fr)
NO (1)	NO315560B1 (fr)
NZ (1)	NZ500652A (fr)
OA (1)	OA11226A (fr)
PA (1)	PA8452001A1 (fr)
PE (1)	PE79999A1 (fr)
PL (1)	PL337497A1 (fr)
SK (1)	SK168299A3 (fr)
TN (1)	TNSN98084A1 (fr)
TW (2)	TW200418871A (fr)
UA (1)	UA70298C2 (fr)
UY (1)	UY25041A1 (fr)
WO (1)	WO1998056801A1 (fr)
YU (1)	YU62999A (fr)
ZA (1)	ZA985016B (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6339063B1 (en)	1997-09-10	2002-01-15	Merck & Co., Inc.	9a-azalides as veterinary antimicrobial agents
ES2281136T3 (es) *	1997-09-10	2007-09-16	Merial Ltd.	Uso de 9a-azalidos como agentes antimicrobiales veterinarios.
EP1779853A3 (fr) *	1997-09-10	2010-01-27	Merial Ltd.	9a-azalides en tant qu'agents anti-microbiens à usage vétérinaire
AP9801420A0 (en) *	1998-01-02	1998-12-31	Pfizer Prod Inc	Novel macrolides.
EP1437360A3 (fr) *	1998-08-19	2005-04-06	Pfizer Products Inc.	C11-carbamates des macrolides antibactériens
US6043227A (en) *	1998-08-19	2000-03-28	Pfizer Inc.	C11 carbamates of macrolide antibacterials
US6100240A (en) *	1998-10-09	2000-08-08	Pfizer Inc	Macrolide derivatives
TR200101241T2 (tr)	1998-11-03	2001-09-21	Pfizer Products Inc.	Yeni makrolit antibiyotikler
CA2411293A1 (fr) *	1999-01-28	2000-07-28	Pfizer Products Inc.	Nouveaux azalides et procede de fabrication
DK1206476T3 (da) *	1999-08-24	2006-05-15	Abbott Lab	9a-azalider med antibakteriel virkning
US6764996B1 (en)	1999-08-24	2004-07-20	Abbott Laboratories	9a-azalides with antibacterial activity
BRPI0017013B1 (pt)	2000-01-27	2015-07-14	Zoetis P Llc	Composição de antibiótico azalídeo e método para sua obtenção
RU2263117C2 (ru) *	2001-04-27	2005-10-27	Пфайзер Продактс Инк.	Способ получения 4"-замещенных производных 9-деоксо-9а-аза-9а-гомоэритромицина а
JP2003040782A (ja) *	2001-05-31	2003-02-13	Pfizer Prod Inc	アザリド抗生物質組成物
AU2003264917A1 (en)	2002-07-08	2004-01-23	Pliva - Istrazivacki Institut D.O.O.	Hybrid molecules of macrolides with steroid/non-steroid anti-inflammatory, antineoplastic and antiviral active molecules
EP1521763A2 (fr) *	2002-07-08	2005-04-13	Pliva - Istrazivacki Institut d.o.o.	Substances anti-inflammatoires non steroidiennes, compositions et procedes d'utilisation de celles-ci
RS20050008A (sr)	2002-07-08	2007-06-04	Pliva-Istraživački Institut D.O.O.,	Nova jedinjenja,kompozicije i metode za lečenje inflamatornih oboljenja i stanja
TW200420573A (en)	2002-09-26	2004-10-16	Rib X Pharmaceuticals Inc	Bifunctional heterocyclic compounds and methods of making and using same
EP1638549A4 (fr) *	2003-03-10	2011-06-15	Optimer Pharmaceuticals Inc	Nouveaux agents antibacteriens
WO2005030227A1 (fr)	2003-09-23	2005-04-07	Enanta Pharmaceuticals, Inc.	Derives 9a-azalide 11-3c-bicycliques
EP1723159B1 (fr)	2004-02-27	2019-06-12	Melinta Therapeutics, Inc.	Composes macrocycliques et leurs procedes de fabrication et d'utilisation
JPWO2009019868A1 (ja)	2007-08-06	2010-10-28	大正製薬株式会社	１０ａ、１２位架橋型１０ａ−アザライド化合物
EP2214484A4 (fr)	2007-10-25	2013-01-02	Cempra Pharmaceuticals Inc	Procédé pour la préparation d'agents antibactériens macrolides
US8299035B2 (en)	2008-05-15	2012-10-30	Taisho Pharmaceutucal Co., Ltd.	10a-azalide compound having 4-membered ring structure
JP5711135B2 (ja)	2008-10-24	2015-04-30	センプラファーマシューティカルズ，インコーポレイテッド	胃腸疾患を治療するための方法
US9937194B1 (en)	2009-06-12	2018-04-10	Cempra Pharmaceuticals, Inc.	Compounds and methods for treating inflammatory diseases
WO2012038372A1 (fr) *	2010-09-20	2012-03-29	Novartis Ag	Nouveau procédé de préparation de 9-déoxo-9a-aza-9a-homoérythromycine a modifiée dans le c-4'' du cycle cladinose par un groupe époxyde
AR085286A1 (es) *	2011-02-21	2013-09-18	Taisho Pharmaceutical Co Ltd	Derivado de macrolido sustituido en la posicion c-4
NZ700182A (en)	2012-03-27	2017-02-24	Cempra Pharmaceuticals Inc	Parenteral formulations for administering macrolide antibiotics
JP5857008B2 (ja) *	2012-08-20	2016-02-10	大正製薬株式会社	Ｃ−４”位置換マクロライド誘導体を含有する医薬
JP6437523B2 (ja)	2013-04-04	2018-12-12	プレジデントアンドフェローズオブハーバードカレッジ	マクロライドならびにそれらの調製および使用の方法
CN103965273B (zh) *	2013-08-23	2016-05-25	普莱柯生物工程股份有限公司	一种大环内酯类化合物
CN105669798B (zh) *	2013-08-23	2019-07-26	普莱柯生物工程股份有限公司	一种大环内酯类化合物
AR102810A1 (es)	2014-08-18	2017-03-29	Taisho Pharmaceutical Co Ltd	Derivado de macrólido sustituido en la posición c-4
CN106998685A (zh)	2014-10-08	2017-08-01	哈佛大学的校长及成员们	14‑元酮内酯及其制备和使用方法
EP3273969A4 (fr)	2015-03-25	2018-11-21	President and Fellows of Harvard College	Macrolides à sucres modifiés de type désosamine et utilisations de ceux-ci
CN108003207B (zh)	2017-12-19	2019-05-10	海门慧聚药业有限公司	制备泰拉霉素的方法
TWI830987B (zh) *	2020-03-12	2024-02-01	美商碩騰服務公司	免疫調節脲氮雜內酯

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4474768A (en) *	1982-07-19	1984-10-02	Pfizer Inc.	N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
US4517359A (en) *	1981-03-06	1985-05-14	Sour Pliva Farmaceutska, Kemijska Prehrambena I Kozmeticka Industrija, N.Sol.O.	11-Methyl-11-aza-4-0-cladinosyl-6-0-desosaminyl-15-ethyl-7,13,14-trihydroxy-3,5,7,9,12,14-hexamethyl-oxacyclopentadecane-2-one and derivatives thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4150220A (en) *	1977-02-04	1979-04-17	Pfizer Inc.	Semi-synthetic 4"-erythromycin A derivatives
SE445223B (sv) *	1977-02-04	1986-06-09	Pfizer	Sett att framstella 4"-amino-erytomylin-a-derivat
DE3475073D1 (en) *	1983-09-06	1988-12-15	Pfizer	Azahomoerythromycin b derivatives and intermediates thereof
US4512982A (en) *	1984-04-13	1985-04-23	Pfizer Inc.	9α-Aza-9α-homoerythromycin compounds, pharmaceutical composition and therapeutic method
CA2064634C (fr) *	1991-04-04	1998-08-04	James V. Heck	Derives de 9-desoxo-8a-aza-8a-homoerythromycine a modifies en positions 4"- et 8a
US5441939A (en) *	1994-03-04	1995-08-15	Pfizer Inc.	3"-desmethoxy derivatives of erythromycin and azithromycin
US5412982A (en) *	1994-03-10	1995-05-09	Potts; James K.	Windsock support

1998
- 1998-05-20 HN HN1998000074A patent/HN1998000074A/es unknown
- 1998-05-22 PA PA19988452001A patent/PA8452001A1/es unknown
- 1998-05-25 SK SK1682-99A patent/SK168299A3/sk unknown
- 1998-05-25 UA UA99126737A patent/UA70298C2/uk unknown
- 1998-05-25 DE DE69832486T patent/DE69832486T2/de not_active Expired - Fee Related
- 1998-05-25 NZ NZ500652A patent/NZ500652A/en unknown
- 1998-05-25 AT AT98919414T patent/ATE310742T1/de not_active IP Right Cessation
- 1998-05-25 JP JP50192999A patent/JP3262806B2/ja not_active Expired - Fee Related
- 1998-05-25 PL PL98337497A patent/PL337497A1/xx unknown
- 1998-05-25 KR KR10-1999-7011643A patent/KR100369959B1/ko not_active Expired - Fee Related
- 1998-05-25 CA CA002293397A patent/CA2293397C/fr not_active Expired - Fee Related
- 1998-05-25 ES ES98919414T patent/ES2251081T3/es not_active Expired - Lifetime
- 1998-05-25 CN CNB988060493A patent/CN1145636C/zh not_active Expired - Fee Related
- 1998-05-25 EP EP98919414A patent/EP0988309B1/fr not_active Expired - Lifetime
- 1998-05-25 YU YU62999A patent/YU62999A/sh unknown
- 1998-05-25 EA EA199901014A patent/EA002440B1/ru not_active IP Right Cessation
- 1998-05-25 AU AU72281/98A patent/AU745006C/en not_active Ceased
- 1998-05-25 IL IL13280898A patent/IL132808A/en not_active IP Right Cessation
- 1998-05-25 HU HU0004076A patent/HUP0004076A3/hu unknown
- 1998-05-25 WO PCT/IB1998/000799 patent/WO1998056801A1/fr not_active Ceased
- 1998-05-25 BR BR9810097-1A patent/BR9810097A/pt not_active IP Right Cessation
- 1998-05-25 ID IDW991565A patent/ID24530A/id unknown
- 1998-06-04 AP APAP/P/1998/001254A patent/AP1189A/en active
- 1998-06-08 TW TW093111859A patent/TW200418871A/zh unknown
- 1998-06-08 GT GT199800075A patent/GT199800075A/es unknown
- 1998-06-08 TW TW087109085A patent/TWI224106B/zh active
- 1998-06-08 PE PE1998000469A patent/PE79999A1/es not_active Application Discontinuation
- 1998-06-09 AR ARP980102704A patent/AR013085A1/es active IP Right Grant
- 1998-06-09 MY MYPI98002563A patent/MY133027A/en unknown
- 1998-06-10 ZA ZA9805016A patent/ZA985016B/xx unknown
- 1998-06-10 DZ DZ980125A patent/DZ2515A1/fr active
- 1998-06-10 CO CO98033231A patent/CO4950584A1/es unknown
- 1998-06-10 TN TNTNSN98084A patent/TNSN98084A1/fr unknown
- 1998-06-10 MA MA25106A patent/MA24563A1/fr unknown
- 1998-06-11 UY UY25041A patent/UY25041A1/es not_active IP Right Cessation
- 1998-06-11 HR HR60/049,980A patent/HRP980315A2/hr not_active Application Discontinuation
1999
- 1999-11-16 IS IS5250A patent/IS1979B/is unknown
- 1999-12-03 OA OA9900270A patent/OA11226A/en unknown
- 1999-12-08 BG BG103969A patent/BG64357B1/bg unknown
- 1999-12-10 NO NO19996107A patent/NO315560B1/no unknown

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4517359A (en) *	1981-03-06	1985-05-14	Sour Pliva Farmaceutska, Kemijska Prehrambena I Kozmeticka Industrija, N.Sol.O.	11-Methyl-11-aza-4-0-cladinosyl-6-0-desosaminyl-15-ethyl-7,13,14-trihydroxy-3,5,7,9,12,14-hexamethyl-oxacyclopentadecane-2-one and derivatives thereof
US4474768A (en) *	1982-07-19	1984-10-02	Pfizer Inc.	N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor

Also Published As

Publication number	Publication date
NZ500652A (en)	2001-10-26
UA70298A (uk)	2004-10-15
CO4950584A1 (es)	2000-09-01
KR100369959B1 (ko)	2003-02-12
CA2293397A1 (fr)	1998-12-17
IS1979B (is)	2005-01-14
EA002440B1 (ru)	2002-04-25
TW200418871A (en)	2004-10-01
IL132808A0 (en)	2001-03-19
JP2000514097A (ja)	2000-10-24
PE79999A1 (es)	1999-08-25
JP3262806B2 (ja)	2002-03-04
EA199901014A1 (ru)	2000-06-26
ZA985016B (en)	1999-12-10
SK168299A3 (en)	2000-09-12
UY25041A1 (es)	2000-09-29
HK1025974A1 (en)	2000-12-01
EP0988309B1 (fr)	2005-11-23
AU745006B2 (en)	2002-03-07
ATE310742T1 (de)	2005-12-15
ES2251081T3 (es)	2006-04-16
DZ2515A1 (fr)	2003-02-01
NO996107L (no)	2000-02-10
CN1145636C (zh)	2004-04-14
AP1189A (en)	2003-07-16
CN1259955A (zh)	2000-07-12
KR20010013633A (ko)	2001-02-26
IL132808A (en)	2004-08-31
AP9801254A0 (en)	1998-06-30
NO315560B1 (no)	2003-09-22
CA2293397C (fr)	2004-08-31
HUP0004076A3 (en)	2003-05-28
MA24563A1 (fr)	1998-12-31
MY133027A (en)	2007-10-31
ID24530A (id)	2000-07-20
DE69832486D1 (de)	2005-12-29
YU62999A (sh)	2002-10-18
HN1998000074A (es)	1999-01-08
IS5250A (is)	1999-11-16
GT199800075A (es)	1999-11-30
HRP980315A2 (en)	1999-04-30
AR013085A1 (es)	2000-12-13
PA8452001A1 (es)	2000-05-24
WO1998056801A1 (fr)	1998-12-17
AU745006C (en)	2006-02-23
HUP0004076A2 (hu)	2001-04-28
NO996107D0 (no)	1999-12-10
TWI224106B (en)	2004-11-21
EP0988309A1 (fr)	2000-03-29
AU7228198A (en)	1998-12-30
PL337497A1 (en)	2000-08-28
DE69832486T2 (de)	2006-07-27
UA70298C2 (uk)	2004-10-15
TNSN98084A1 (fr)	2005-03-15
BG103969A (en)	2000-07-31
BR9810097A (pt)	2000-08-08
OA11226A (en)	2003-07-16

Publication	Publication Date	Title
EP0988309B1 (fr)	2005-11-23	Derives de macrolide substitue en c-4''
US6420536B1 (en)	2002-07-16	4″-substituted-9-deoxo-9a-aza-9a-homoerythromycin a derivatives
US6576749B2 (en)	2003-06-10	C-4″-substituted macrolide derivatives
EP1131331B1 (fr)	2004-03-03	Azalides a 13 elements et leur utilisation en tant qu'antibiotiques
US6043227A (en)	2000-03-28	C11 carbamates of macrolide antibacterials
MXPA99011496A (en)	2000-07-01	C-4''-substituted macrolide derivatives
CZ438999A3 (cs)	2000-05-17	C-4"- substituované makrolidové deriváty
MXPA99011495A (en)	2001-05-17	4"-substituted-9-deoxo-9a-aza-9a-homoerythromycin a derivatives
HK1088014B (en)	2010-09-30	4"-substituted-9-deoxo-9a-aza-9a-homoerythromy a derivatives